PL2400298T3 - Sposób hodowania pojedynczych komórek b oraz wytwarzania swoistych przeciwciał - Google Patents
Sposób hodowania pojedynczych komórek b oraz wytwarzania swoistych przeciwciałInfo
- Publication number
- PL2400298T3 PL2400298T3 PL10005602T PL10005602T PL2400298T3 PL 2400298 T3 PL2400298 T3 PL 2400298T3 PL 10005602 T PL10005602 T PL 10005602T PL 10005602 T PL10005602 T PL 10005602T PL 2400298 T3 PL2400298 T3 PL 2400298T3
- Authority
- PL
- Poland
- Prior art keywords
- specific antibody
- antibody production
- cultivation method
- cell cultivation
- cell
- Prior art date
Links
- 210000003719 b-lymphocyte Anatomy 0.000 title 1
- 238000004113 cell culture Methods 0.000 title 1
- 230000016784 immunoglobulin production Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/72—Undefined extracts from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/231—Interleukin-10 (IL-10)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1157—Monocytes, macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1185—Thymus cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/70—Non-animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
- G01N2015/016—White blood cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10005602.7A EP2400298B1 (en) | 2010-05-28 | 2010-05-28 | Single B-cell cultivation method and specific antibody production |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2400298T3 true PL2400298T3 (pl) | 2014-01-31 |
Family
ID=42396427
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL10005602T PL2400298T3 (pl) | 2010-05-28 | 2010-05-28 | Sposób hodowania pojedynczych komórek b oraz wytwarzania swoistych przeciwciał |
PL17169362T PL3239708T3 (pl) | 2010-05-28 | 2011-05-26 | Sposób hodowania pojedynczego limfocytu b |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL17169362T PL3239708T3 (pl) | 2010-05-28 | 2011-05-26 | Sposób hodowania pojedynczego limfocytu b |
Country Status (15)
Country | Link |
---|---|
US (4) | US20130084637A1 (pl) |
EP (4) | EP2400298B1 (pl) |
JP (3) | JP5779239B2 (pl) |
KR (1) | KR101495976B1 (pl) |
CN (2) | CN105039252B (pl) |
BR (1) | BR112012025695B1 (pl) |
CA (2) | CA3008822C (pl) |
DK (1) | DK2400298T3 (pl) |
ES (3) | ES2434256T3 (pl) |
HK (2) | HK1181112A1 (pl) |
MX (2) | MX2012013437A (pl) |
PL (2) | PL2400298T3 (pl) |
RU (1) | RU2709531C2 (pl) |
SI (1) | SI2400298T1 (pl) |
WO (1) | WO2011147903A1 (pl) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013092716A1 (en) | 2011-12-21 | 2013-06-27 | F. Hoffmann-La Roche Ag | Rapid method for cloning and expression of cognate antibody variable region gene segments |
US10017739B2 (en) | 2012-09-06 | 2018-07-10 | Duke University | Methods of expanding and assessing B cells and using expanded B cells to treat disease |
EP2727941A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
EP2727943A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Trispecific antibodies against human EGFR, HER2 and HER3 |
EP2727942A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Bispecific antibodies against human EGFR, HER2, and HER3 |
US20150259430A1 (en) | 2012-11-05 | 2015-09-17 | Mab Discovery Gmbh | Method for the production of multispecific antibodies |
PT2971039T (pt) | 2013-03-14 | 2020-05-06 | Immusoft Corp | Métodos para diferenciação e transdução in vitro de células b de memória com vetores virais pseudotipados vsv-g |
KR20150140679A (ko) * | 2013-03-15 | 2015-12-16 | 앨더 바이오파마슈티컬즈, 인코포레이티드 | 항원-특이적 b 세포를 확인하고 단리시키고, 원하는 항원에 대한 항체를 생성하기 위한 프로토콜 |
CN104232577B (zh) * | 2013-06-20 | 2017-12-01 | 中国人民解放军军事医学科学院基础医学研究所 | 一种获得自身反应性b细胞的方法 |
ES2927905T3 (es) * | 2013-12-24 | 2022-11-11 | Kling Biotherapeutics B V | Producción de anticuerpos ex vivo |
EP3960765A1 (en) | 2015-06-26 | 2022-03-02 | Sanofi Biotechnology SAS | Monoclonal anti-il-1racp antibodies |
EP3378488A4 (en) | 2015-11-18 | 2019-10-30 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR ENHANCING THE HUMORAL IMMUNE RESPONSE |
JP7026634B2 (ja) | 2016-03-30 | 2022-02-28 | エフ.ホフマン-ラ ロシュ アーゲー | B細胞培養法 |
EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
CN106222137A (zh) * | 2016-08-24 | 2016-12-14 | 南昌大学 | 一种体外活化人记忆性b细胞成浆细胞的培养方法 |
EP3554515A4 (en) | 2016-12-15 | 2020-08-26 | Duke University | B10 REGULATORY CELL DEPLETION ANTIBODIES AND METHODS AND THEIR USE IN COMBINATION WITH IMMUNITY CHECKPOINT INHIBITORS |
JP6916884B2 (ja) * | 2017-01-02 | 2021-08-11 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | B細胞培養法 |
EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
WO2018210896A1 (en) | 2017-05-19 | 2018-11-22 | F. Hoffmann-La Roche Ag | Method for the production of thymocyte supernatant |
US12009521B2 (en) * | 2017-11-08 | 2024-06-11 | Sharp Kabushiki Kaisha | Negative electrode for batteries, battery, and method for producing battery |
CN111417719B (zh) * | 2017-11-30 | 2023-08-29 | 豪夫迈·罗氏有限公司 | B细胞培养方法 |
CN108588019B (zh) * | 2018-05-03 | 2019-04-02 | 首都医科大学附属北京朝阳医院 | 一种体外诱导初始b细胞分化为调节性b细胞的方法及其培养条件 |
CN109234232A (zh) * | 2018-09-30 | 2019-01-18 | 杭州华安单抗生物技术有限公司 | 兔外周血b细胞的培养体系及培养方法、抗体的制备方法和应用 |
EP3902830A1 (en) * | 2018-12-30 | 2021-11-03 | F. Hoffmann-La Roche AG | Anti-rabbit cd19 antibodies and methods of use |
US20230158074A1 (en) * | 2020-04-16 | 2023-05-25 | The General Hospital Corporation | B cell immunomodulatory therapy for acute respiratory distress syndrome |
CN111518765B (zh) * | 2020-05-12 | 2021-01-26 | 优睿赛思(武汉)生物科技有限公司 | 一种b淋巴细胞体外培养体系及应用 |
TW202428613A (zh) | 2022-09-21 | 2024-07-16 | 法商賽諾菲生物技術公司 | 人源化抗il-1r3抗體及使用方法 |
WO2024208936A1 (en) | 2023-04-05 | 2024-10-10 | F. Hoffmann-La Roche Ag | In vitro cultivation method for antibody expressing cells |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58116678A (ja) * | 1981-12-28 | 1983-07-11 | Ajinomoto Co Inc | 浮遊性動物細胞の培養法およびその装置 |
JPS58216125A (ja) * | 1982-06-09 | 1983-12-15 | Asahi Chem Ind Co Ltd | ヒト抗体の産生方法 |
WO1991016418A1 (en) * | 1990-04-17 | 1991-10-31 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Feeder cells for monoclonal antibody production |
US5387940A (en) * | 1993-07-07 | 1995-02-07 | Rca Thomson Licensing Corporation | Method and apparatus for providing scaleable compressed video signal |
EP0728013A4 (en) * | 1993-11-10 | 1999-09-15 | Jackson H M Found Military Med | COMPOSITION AND METHOD FOR THE STIMULATION OF THE ANTIBODY RELEASE BY THROUGH LYMPHOCYTES |
US5811524A (en) * | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
US6541225B1 (en) * | 2000-01-26 | 2003-04-01 | Raven Biotechnologies, Inc. | Methods and compositions for generating human monoclonal antibodies |
US7816134B2 (en) * | 2000-08-16 | 2010-10-19 | Takara Bio Inc. | Method of extensive culture of antigen-specific cytotoxic T cells |
US20060051348A1 (en) | 2004-09-09 | 2006-03-09 | Jorn Gorlach | Method of producing a plurality of isolated antibodies to a plurality of cognate antigens |
US20070031550A1 (en) | 2005-08-15 | 2007-02-08 | Samson Allan D | Method for continuously processing meat substrates |
WO2007031550A2 (en) * | 2005-09-15 | 2007-03-22 | Crucell Holland B.V. | Method for preparing immunoglobulin libraries |
JP2009511067A (ja) * | 2005-10-14 | 2009-03-19 | メディミューン,エルエルシー | 抗体ライブラリーの細胞提示 |
DK1974017T4 (da) * | 2005-12-09 | 2023-09-25 | Academisch Medisch Centrum Bij De Univ Van Amsterdam | Midler og fremgangsmåder til at påvirke stabiliteten af antistof producerende celler |
NZ569816A (en) * | 2005-12-16 | 2011-10-28 | Ribovax Biotechnologies Sa | Methods for obtaining immortalized antibody secreting cells |
WO2008045140A1 (en) * | 2006-05-19 | 2008-04-17 | Alder Biopharmaceuticals, Inc. | Culture method for obtaining a clonal population of antigen-specific b cells |
US8642307B2 (en) | 2006-05-25 | 2014-02-04 | Nalge Nunc International Corporation | Cell culture surface chemistries |
CA2688146C (en) | 2007-05-21 | 2018-03-06 | Alder Biopharmaceuticals, Inc. | Antibodies to il-6 and use thereof |
US8404235B2 (en) * | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US8999707B2 (en) * | 2008-01-28 | 2015-04-07 | Thomas Jefferson University | Method of making hybrid cells that express useful antibodies |
US8394583B2 (en) * | 2008-07-24 | 2013-03-12 | The Board Of Regents Of The University Of Texas System | VH4 codon signature for multiple sclerosis |
DK2352763T4 (da) * | 2008-10-01 | 2022-10-17 | Amgen Res Munich Gmbh | Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener |
JP5837820B2 (ja) * | 2008-10-22 | 2015-12-24 | インスティテュート・フォー・リサーチ・イン・バイオメディシンInstitute For Research In Biomedicine | 形質細胞から抗体を産生する方法 |
EP2233502A1 (en) * | 2009-03-27 | 2010-09-29 | Deutsches Rheuma-Forschungszentrum Berlin | Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them |
SG175305A1 (en) * | 2009-04-23 | 2011-11-28 | Theraclone Sciences Inc | Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies |
WO2011046623A2 (en) * | 2009-10-16 | 2011-04-21 | Duke University | Hiv-1 antibodies |
-
2010
- 2010-05-28 SI SI201030367T patent/SI2400298T1/sl unknown
- 2010-05-28 DK DK10005602.7T patent/DK2400298T3/da active
- 2010-05-28 ES ES10005602T patent/ES2434256T3/es active Active
- 2010-05-28 EP EP10005602.7A patent/EP2400298B1/en active Active
- 2010-05-28 PL PL10005602T patent/PL2400298T3/pl unknown
-
2011
- 2011-05-26 ES ES17169362T patent/ES2858450T3/es active Active
- 2011-05-26 CA CA3008822A patent/CA3008822C/en active Active
- 2011-05-26 MX MX2012013437A patent/MX2012013437A/es active IP Right Grant
- 2011-05-26 KR KR1020127030603A patent/KR101495976B1/ko active IP Right Grant
- 2011-05-26 MX MX2015001467A patent/MX345884B/es unknown
- 2011-05-26 CN CN201510482333.7A patent/CN105039252B/zh active Active
- 2011-05-26 EP EP17169362.5A patent/EP3239708B1/en active Active
- 2011-05-26 RU RU2015155197A patent/RU2709531C2/ru active
- 2011-05-26 CN CN201180026559.6A patent/CN102918395B/zh active Active
- 2011-05-26 PL PL17169362T patent/PL3239708T3/pl unknown
- 2011-05-26 ES ES11722402.2T patent/ES2632928T3/es active Active
- 2011-05-26 JP JP2013510646A patent/JP5779239B2/ja active Active
- 2011-05-26 EP EP11722402.2A patent/EP2577304B1/en active Active
- 2011-05-26 CA CA2798286A patent/CA2798286C/en active Active
- 2011-05-26 EP EP20214670.0A patent/EP3825690A1/en active Pending
- 2011-05-26 BR BR112012025695-5A patent/BR112012025695B1/pt active IP Right Grant
- 2011-05-26 WO PCT/EP2011/058616 patent/WO2011147903A1/en active Application Filing
-
2012
- 2012-11-27 US US13/686,538 patent/US20130084637A1/en not_active Abandoned
-
2013
- 2013-07-15 HK HK13108297.8A patent/HK1181112A1/xx unknown
-
2015
- 2015-07-10 JP JP2015138308A patent/JP6204415B2/ja active Active
-
2016
- 2016-01-19 HK HK16100556.8A patent/HK1212731A1/zh unknown
- 2016-05-06 US US15/148,861 patent/US20160251621A1/en not_active Abandoned
-
2017
- 2017-05-16 JP JP2017097126A patent/JP6353953B2/ja active Active
-
2018
- 2018-03-27 US US15/937,456 patent/US20180298335A1/en not_active Abandoned
-
2020
- 2020-06-12 US US16/900,793 patent/US20210062149A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2400298T3 (pl) | Sposób hodowania pojedynczych komórek b oraz wytwarzania swoistych przeciwciał | |
EP2712928A4 (en) | PROCESS FOR THE PRODUCTION OF NATURAL CARBOHYDRATE BY FERMENTATION AND ITS APPLICATIONS | |
EP2624066A4 (en) | LOADING ELEMENT AND METHOD FOR THE MANUFACTURE THEREOF | |
EP2613203A4 (en) | LOADING ELEMENT AND PROCESS FOR PRODUCING THE SAME | |
PT2563739T (pt) | Método para produção de tijolos utilizando bactérias produtoras de enzimas | |
EP2657188A4 (en) | FLUOROGRAPHIC AND METHOD FOR PREPARING THE SAME | |
HK1248242A1 (zh) | 動物細胞的培養方法 | |
PL2614193T3 (pl) | Element termoizolacyjny i sposób jego wytwarzania | |
GB201000688D0 (en) | Product and method | |
EP2618139A4 (en) | BIOSENSOR AND METHOD FOR PRODUCING THE SAME | |
HU1000330D0 (en) | Novel method | |
IL228546A0 (en) | fermentation process | |
SI2553082T1 (sl) | Postopek in naprava za proizvodnjo bioplina | |
GB201106261D0 (en) | Hydrolysis and fermentation process | |
ZA201304024B (en) | Fermentation process involving adjusting specific co-uptake | |
SG11201400405TA (en) | Caninised antibodies and method for the production of same | |
EP2578725A4 (en) | COATED ELEMENT AND METHOD FOR PRODUCING THE SAME | |
EP2722159A4 (en) | STRUCTURE AND MANUFACTURING METHOD THEREFOR | |
EP2636497A4 (en) | METHOD FOR PRODUCING ORNAMENT | |
SG10201602874VA (en) | Protein production method | |
EP2622965A4 (en) | FERMENTED FOOD AND METHOD OF MANUFACTURING THE SAME | |
PL2554656T3 (pl) | Sposób hodowli drożdży | |
PL2565259T3 (pl) | Sposób i urządzenie do wytwarzania biogazu | |
EP2605916A4 (en) | CALENDAR AND CALENDAR MANUFACTURING PROCESS | |
HK1176995A1 (en) | Biosensor and methods for manufacturing |